Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corp
(NQ:
BPMC
)
108.52
+4.60 (+4.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
Blueprint Medicines Stock Is Getting Hammered Wednesday: What's Happening?
August 17, 2022
Blueprint Medicines Corp (NASDAQ: BPMC) shares are trading lower by 22.2% to $53.32 Wednesday morning after the company announced top-line results from the registrational Part 2 of the PIONEER clinical...
Via
Benzinga
Data From Blueprint Medicines' Blood Disorder Trial Fails To Lift Shares
August 17, 2022
Blueprint Medicines Corporation (NASDAQ: BPMC)
Via
Benzinga
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
August 17, 2022
Blueprint Medicines met all its goals, but the results paled from an earlier study.
Via
Investor's Business Daily
Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study
August 17, 2022
Blueprint Medicines (NASDAQ: BPMC) announced positive top-line results from the Part 2 of PIONEER clinical trial of AYVAKIT (avapritinib) in patients with non-advanced systemic mastocytosis (SM).
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 17, 2022
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
August 03, 2022
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Via
Benzinga
Blueprint Medicines: Q2 Earnings Insights
August 02, 2022
Blueprint Medicines (NASDAQ:BPMC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
4 Analysts Have This to Say About Blueprint Medicines
June 10, 2022
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Blueprint Medicines: Q1 Earnings Insights
May 03, 2022
Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
A Preview Of Blueprint Medicines's Earnings
August 01, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
3 Biotech Stock Picks From This Wedbush Analyst
July 27, 2022
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.
Via
Benzinga
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
July 16, 2022
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. The USD Fund VIII has $2.5 billion and the first...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
July 08, 2022
Via
Benzinga
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
June 30, 2022
Via
Benzinga
What 7 Analyst Ratings Have To Say About Blueprint Medicines
June 27, 2022
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
June 27, 2022
Upgrades
Via
Benzinga
SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know
June 13, 2022
SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32%...
Via
Benzinga
10 Biggest Price Target Changes For Monday
June 13, 2022
RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading.
Via
Benzinga
91 Biggest Movers From Friday
June 13, 2022
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Via
Benzinga
44 Stocks Moving In Friday's Mid-Day Session
June 10, 2022
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
June 10, 2022
Via
Benzinga
What You Missed On Wall Street On Thursday
June 10, 2022
Here are our top five lists with the news and calls moving stocks, that you better not have missed yesterday...
Via
Talk Markets
Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug
June 09, 2022
The FDA had a suggestion for Blueprint's midstage systemic mastocytosis test.
Via
Investor's Business Daily
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
June 03, 2022
Bristol Myers is moving deeper into the targeted oncology space.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
June 01, 2022
Upgrades
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
June 01, 2022
Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading.
Via
Benzinga
What 3 Analyst Ratings Have To Say About Blueprint Medicines
May 19, 2022
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Preview: Blueprint Medicines
May 02, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.